Innovation for Healthcare

---

"AI, design thinking, robotics, and big data have made a splash across all industries, but perhaps their greatest impact is in healthcare. As technology and innovation have grown in the healthcare field, hospitals and startups have found amazing ways to improve their offerings and revolutionize the industry. The result is amazing applications of new technology and thinking that can forever change how patients are treated."  Forbes

At Acumen Health we offer a differentiated value offering by combining our expertise and capabilities in healthcare, biopharma, IT, big data and predictive analytics, machine learning and artificial intelligence to be at the forefront of both innovating and with the assistance of the operational implementation of innovation models, systems and programs for current and emerging healthcare players. 

As of 2020 and Worldwide, there are 42 healthcare unicorns worth a combined $99.5B: Healthcare startups closed 1,156 funding rounds in Q1’20, the lowest level since Q4’18. Despite the reduction, equity funding continued to rise, surpassing $14.6B. Innovation in Healthcare remains as one of the hottest topics for investors and Big Tech.

Healthcare stakeholders responded to the present crisis by providing new and expanded product offerings, adjusting regulatory policies, and creating collaborative partnerships. Going forward, tech giants will likely play a larger role in their strategy and implementation of future public health responses. 

Amid the present pandemic, both telehealth deals and public interest (through searches) doubled from Q4’19. Several payers and providers expanded access to virtual care, and telehealth companies from around the globe reported significant upticks in visit volume and investor interest.

During the quarter Q1 2020, telehealth startups closed 103 deals, double the amount seen in Q4’19 and the highest level on record.

Deals to three cell therapy startups ranked among the top 10 healthcare deals globally for the first quarter of 2020. Within the regenerative medicine space, cell-based immuno-oncology startups closed some of the largest rounds and were a focal point of M&A and IPO activity.